Immuneering (IMRX) Gross Margin (2020 - 2022)

Immuneering's Gross Margin history runs 3 years deep, the most recent figure standing at 100.0% for Q4 2022.

• In Q4 2022, Gross Margin rose 10877.0% year-over-year to 100.0%; the TTM figure through Sep 2023 stood at 100.0% (up 7199.0% YoY), while the FY2022 annual figure was 50.11%, up 555.0% from the prior year.
• Gross Margin was 100.0% for Q4 2022 at Immuneering, up from 49.6% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2022 to a low of 8.77% in Q4 2021.
• Historically, Gross Margin has averaged 47.78% across 3 years, with a median of 50.55% in 2022.
• The sharpest annual moves came in 2021 and 2022: Gross Margin plunged 3762 bps in 2021, then soared 10877 bps in 2022.
• A 3-year view of Gross Margin shows it stood at 28.85% in 2020, then sank by 130 bps to 8.77% in 2021, then surged by 1240 bps to 100.0% in 2022.
• The last three Gross Margin figures came in at 100.0% (Q4 2022), 49.6% (Q3 2022), and 49.23% (Q2 2022), per Business Quant data.